聚乙二醇干扰素联合利巴韦林治疗不同基因型慢性丙型肝炎疗效分析

陈庆峰

doi:10.13898/j.cnki.issn.1000-2200.2016.09.016

聚乙二醇干扰素联合利巴韦林治疗不同基因型慢性丙型肝炎疗效分析

陈庆峰

Efficacy of the pegylated interferon combined with ribavirin in the treatment of different virus genotype chronic hepatitis C

CHEN Qing-feng

摘要

摘要: 目的：探讨聚乙二醇干扰素联合利巴韦林治疗不同基因型慢性丙型肝炎（丙肝）的疗效。方法：80例丙肝患者，采用特异性探针杂交法进行丙肝病毒（HCV）基因型分型，根据病毒基因型分型结果分成HCV 1b型组和非1b型组，2组均给予聚乙二醇干扰素（1.5 μg/kg皮下注射）和口服利巴韦林，治疗前后及随访中检测高灵敏HCV RNA作为疗效评价的指标。获得各组持续病毒学应答率，并比较2组持续病毒学应答率。结果： HCV 1b型组与非1b型组获得持续病毒学应答率分别为58.1%和86.5%，2组比较差异有统计学意义（P<0.01）。结论：聚乙二醇干扰素联合利巴韦林治疗HCV1b基因型疗效不佳，丙肝的疗效与基因型密切相关。

Abstract: Objective: To observe the clinical effects of pegylated interferon(PegIFN) combined with ribaririn in the treatment of chronic hepatitis C.Methods: Eighty hepatitis C patients were divided into the hepatitis C virus(HCV)lb group and non-HCV 1b group according to the genotype of HCV.The two groups were treated with PegIFN(1.5 μg/kg) by subcutaneous injection combined with ribavirin by oral.The HCV ribonucleic acid(RNA) in two groups were detected before and after treatment.The rates of sustained virological response in two groups were compared.Results: The rates of sustained virological response in HCV lb group and non-HCV 1b group were 58.1% and 86.5%,the difference of which was statistically significant(P<0.01).Conclusions: The effect of Peg-interferon combined with ribavirin in treating HCV 1b is unsatisfactory,and the treatment effect of HCV is closely related to the genotype of HCV.

HTML全文

参考文献(12)

施引文献

资源附件(0)